Adding Vosaroxin to Cytarabine May Benefit Some with Acute Myeloid Leukemia

Share this content:
Addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory AML.
Addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory AML.

The addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory acute myeloid leukemia (AML), a new study published online ahead of print in the journal The Lancet Oncology has shown.

For the phase 3 trial, researchers sought to assess the safety and efficacy of vosaroxin plus cytarabine in patients with relapsed or refractory AML. Vosaroxin is a first-in-class anticancer quinolone derivative and topoisomerase II inhibitor.

Researchers enrolled 711 patients with AML who had refractory disease or were in first relapse after one or two cycles of previous induction chemotherapy, including at least one cycle of cytarabine plus an anthracycline. 

Participants were randomly assigned 1:1 to receive cytarabine 1 g/m2 IV on days 1-5 in combination with vosaroxin 90 mg/m2 IV on days 1 and 4 in the first cycle and 70 mg/m2 in subsequent cycles or placebo.

Results showed that median overall survival was 7.5 months (95% CI: 6.4, 8.5) in the vosaroxin arm and 6.1 months (95% CI: 5.2, 7.1) in the placebo arm (HR = 0.87; 95% CI: 0.73, 1.02; P=0.024).

Researchers found that 30% of patients in the vosaroxin group achieved a complete remission compared with 16% of those in the placebo group (P<0.0001).

RELATED: Modified FCR Regimen No More Effective for Previously Untreated Chronic Leukemia

In regard to safety, grade 3 or higher febrile neutropenia, neutropenia, stomatitis, hypokalemia, bacteremia, sepsis, and pneumonia occurred more frequently in those who received the investigational drug versus placebo.

Thirty-day and 60-day all-cause mortality were similar between the two groups.

Reference

  1. Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 trial. Lancet Oncol. 2015. [epub ahead of print]. doi: 10.1016/S1470-2045(15)00201-6.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs